Jean Ann, Rezdiffra patient at pep rally
Jean Ann, Rezdiffra patient at pep rally

Rezdiffra DIFFERENCE

Ask for a treatment that works directly in the liver.

MASH was formerly called NASH (nonalcoholic steatohepatitis).

A breakthrough treatment made for MASH.*

*With moderate to advanced liver scarring without cirrhosis, along with diet and exercise. This indication is approved based on improvement of MASH and liver scarring (fibrosis). There are ongoing studies to confirm the clinical benefit of Rezdiffra.

liver icon
liver and target icon

How it works

Only Rezdiffra works directly in the liver to reactivate liver cells, helping to reduce liver fat.

Study results

Rezdiffra made a difference for patients in a clinical trial.†

helps reduce scarring graphic

Helps reduce liver scarring‡,§

1.5 to ~2x

as many patients taking Rezdiffra vs placebo achieved improvement in liver scarring‡,§

helps reduce MASH graphic

Helps reduce MASH‖,¶

2 to ~3x

as many patients taking Rezdiffra vs placebo achieved a reduction in MASH‖,¶

†Rezdiffra was assessed by 2 credible healthcare providers (A&B).

‡Reduction in scarring defined as improvement in fibrosis with no worsening of steatohepatitis (defined as no increase in score for ballooning, inflammation, or steatosis).

§Improvement in liver scarring in patients taking 100 mg or 80 mg of Rezdiffra vs placebo:

A: 28% (100 mg of Rezdiffra), 23% (80 mg of Rezdiffra) vs 15% (placebo)

B: 24% (100 mg of Rezdiffra), 23% (80 mg of Rezdiffra) vs 13% (placebo)

‖Defined as resolution of steatohepatitis (score of 0-1 for inflammation, 0 for ballooning and any value for steatosis) with no worsening of liver scarring.

MASH resolution in patients taking 100 mg or 80 mg of Rezdiffra vs placebo:

A: 36% (100 mg of Rezdiffra), 27% (80 mg of Rezdiffra) vs 13% (placebo)

B: 24% (100 mg of Rezdiffra), 26% (80 mg of Rezdiffra) vs 9% (placebo)

Rezdiffra made a difference in liver enzymes in as little as 3 months.

On average, liver enzymes appeared to be reduced in patients taking Rezdiffra compared to placebo starting as early as 3 months through 1 year.

Results may vary.

three months through one year graphic

Side effects

Possible side effects.

Rezdiffra may cause serious side effects. Stop taking Rezdiffra and call your doctor if you develop symptoms of:

  • Liver injury (hepatotoxicity): Stop taking Rezdiffra and call your healthcare provider right away if you develop the following signs or symptoms of hepatotoxicity: tiredness, nausea, vomiting, fever, rash, your skin or the white part of your eyes turns yellow (jaundice), or stomach pain/tenderness. 
  • Gallbladder problems: Gallbladder problems such as gallstones, or inflammation of the gallbladder, or inflammation of the pancreas from gallstones can occur with MASH and may occur if you take Rezdiffra. Call your healthcare provider right away if you develop any signs or symptoms of these conditions, including nausea, vomiting, fever, or pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen to your back and the pain may happen with or without vomiting.

Common side effects observed in studies include diarrhea, nausea, itching, stomach pain, vomiting, dizziness, and constipation. 

Diarrhea and nausea were the most common side effects. Both typically began early in treatment and were mild to moderate, lasting ~3 to 4 weeks.

These are not all the possible side effects of Rezdiffra. For more information, ask your healthcare provider or pharmacist.

Rezdiffra medication bottle image

Rezdiffra is a once-daily pill.

Take every day with or without food. Continue taking Rezdiffra as prescribed for as long as your liver specialist advises.

How likely are you to proactively ask for Rezdiffra at your next appointment?

Move the slider and click "Submit" to select a response.

Not Likely

Unsure

Very
Likely

Thank you for your response

Here are some resources that can help you with the conversation.

Thank you for your response

Can you tell us a bit more?

Thank you for your response

Here are some resources that can help you ask your specialist for Rezdiffra.

Here’s some additional information about how Rezdiffra works.

Learn about how diet & exercise alone may not be enough.

Explore savings options through the Madrigal Patient Support program.

Learn what can happen if fatty liver disease or MASH is left unmanaged.

Check out real patients’ experiences on Rezdiffra.

    Julie, Rezdiffra Ambassador circle graphic
    Julie, Rezdiffra Ambassador circle animation

    Rezdiffra is making a difference for Julie. Ask your liver specialist if it’s right for you.

    Important Safety Information and Indication

    Expand Collapse

    Before you take Rezdiffra, tell your healthcare provider about all of your medical conditions, including if you:

    • have any liver problems other than MASH.
    • have gallbladder problems or have been told you have gallbladder problems, including gallstones.
    • are pregnant or plan to become pregnant. It is not known if Rezdiffra will harm your unborn baby.
    • are breastfeeding or plan to breastfeed. It is not known if Rezdiffra passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take Rezdiffra.

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

    • Rezdiffra and other medicines may affect each other, causing side effects. Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works.
    • Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help lower your triglycerides, or cyclosporine to suppress your immune system, because Rezdiffra is not recommended in patients taking these medicines.
    • Tell your healthcare provider if you are taking medicines such as clopidogrel to thin your blood or statin medicines to help lower your cholesterol.
    • Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

    What are the possible side effects of Rezdiffra?

    Rezdiffra may cause serious side effects, including:

    • liver injury (hepatotoxicity). Stop taking Rezdiffra and call your healthcare provider right away if you develop the following signs or symptoms of hepatotoxicity: tiredness, nausea, vomiting, fever, rash, your skin or the white part of your eyes turns yellow (jaundice), or stomach pain/tenderness.
    • gallbladder problems. Gallbladder problems such as gallstones, or inflammation of the gallbladder, or inflammation of the pancreas from gallstones can occur with MASH and may occur if you take Rezdiffra. Call your healthcare provider right away if you develop any signs or symptoms of these conditions, including nausea, vomiting, fever, or pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen to your back and the pain may happen with or without vomiting.

    The most common side effects of Rezdiffra include diarrhea, nausea, itching, stomach pain, vomiting, dizziness, and constipation.

    These are not all the possible side effects of Rezdiffra. For more information, ask your healthcare provider or pharmacist.

    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch. You may also report side effects to Madrigal Pharmaceuticals, Inc. at 1‑800‑905‑0324.

    What is Rezdiffra?

    Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.

    This indication is approved based on improvement of MASH and liver scarring (fibrosis). There are ongoing studies to confirm the clinical benefit of Rezdiffra.

    Please see the full Prescribing Information, including Patient Information, for Rezdiffra.

    Important Safety Information and Indication

    Before you take Rezdiffra, tell your healthcare provider about all of your medical conditions, including if you:

    • have any liver problems other than MASH.
    • have gallbladder problems or have been told you have gallbladder problems, including gallstones.
    • are pregnant or plan to become pregnant. It is not known if Rezdiffra will harm your unborn baby.
    • are breastfeeding or plan to breastfeed. It is not known if Rezdiffra passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take Rezdiffra.

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

    • Rezdiffra and other medicines may affect each other, causing side effects. Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works.
    • Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help lower your triglycerides, or cyclosporine to suppress your immune system, because Rezdiffra is not recommended in patients taking these medicines.
    • Tell your healthcare provider if you are taking medicines such as clopidogrel to thin your blood or statin medicines to help lower your cholesterol.
    • Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

    What are the possible side effects of Rezdiffra?

    Rezdiffra may cause serious side effects, including:

    • liver injury (hepatotoxicity). Stop taking Rezdiffra and call your healthcare provider right away if you develop the following signs or symptoms of hepatotoxicity: tiredness, nausea, vomiting, fever, rash, your skin or the white part of your eyes turns yellow (jaundice), or stomach pain/tenderness.
    • gallbladder problems. Gallbladder problems such as gallstones, or inflammation of the gallbladder, or inflammation of the pancreas from gallstones can occur with MASH and may occur if you take Rezdiffra. Call your healthcare provider right away if you develop any signs or symptoms of these conditions, including nausea, vomiting, fever, or pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen to your back and the pain may happen with or without vomiting.

    The most common side effects of Rezdiffra include diarrhea, nausea, itching, stomach pain, vomiting, dizziness, and constipation.

    These are not all the possible side effects of Rezdiffra. For more information, ask your healthcare provider or pharmacist.

    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch. You may also report side effects to Madrigal Pharmaceuticals, Inc. at 1‑800‑905‑0324.

    What is Rezdiffra?

    Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.

    This indication is approved based on improvement of MASH and liver scarring (fibrosis). There are ongoing studies to confirm the clinical benefit of Rezdiffra.

    Please see the full Prescribing Information, including Patient Information, for Rezdiffra.